02 Jul 2025
Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease based at The Oxford Science Park, has appointed Dr Quin Wills as CEO.
As Founder of Ochre Bio, and previously CSO, Quin has been driving the company’s innovative approach to late-stage liver disease, developing potential new therapeutics to target disease progression. Quin will now lead the company in the next phase of its ambitions: progressing new drug... Read more